TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $7.20 Consensus Price Target from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $6.60.

TCRX has been the topic of several research analyst reports. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Needham & Company LLC decreased their price objective on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. HC Wainwright cut their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th.

TScan Therapeutics Trading Down 5.0%

NASDAQ:TCRX opened at $1.13 on Tuesday. The stock has a market cap of $64.13 million, a price-to-earnings ratio of -1.01 and a beta of 1.00. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average price is $1.85 and its 200-day moving average price is $1.70. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $5.30.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. TScan Therapeutics had a negative return on equity of 67.61% and a negative net margin of 1,692.96%.The firm had revenue of $2.51 million for the quarter, compared to the consensus estimate of $1.98 million. On average, equities research analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TCRX. Hsbc Holdings PLC bought a new stake in TScan Therapeutics during the first quarter valued at approximately $49,000. Checkpoint Capital L.P. boosted its stake in shares of TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock worth $2,784,000 after acquiring an additional 261,663 shares during the last quarter. BVF Inc. IL boosted its stake in shares of TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after acquiring an additional 1,900,000 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares during the period. Finally, Deutsche Bank AG increased its stake in shares of TScan Therapeutics by 149.4% in the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after purchasing an additional 31,481 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.